Maryland State Retirement & Pension System Acquires 3,126 Shares of Moderna, Inc. $MRNA

Maryland State Retirement & Pension System lifted its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 16.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,917 shares of the company’s stock after purchasing an additional 3,126 shares during the period. Maryland State Retirement & Pension System’s holdings in Moderna were worth $4,221,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of MRNA. Advisor Resource Council acquired a new stake in Moderna in the third quarter valued at approximately $283,000. Ritholtz Wealth Management raised its stake in shares of Moderna by 162.7% during the 3rd quarter. Ritholtz Wealth Management now owns 9,001 shares of the company’s stock worth $1,733,000 after buying an additional 5,575 shares during the period. Joel Isaacson & Co. LLC acquired a new position in shares of Moderna during the 3rd quarter worth approximately $240,000. Jacobi Capital Management LLC purchased a new position in shares of Moderna during the 3rd quarter valued at approximately $75,000. Finally, First Command Advisory Services Inc. acquired a new stake in Moderna in the 3rd quarter valued at $164,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on MRNA shares. The Goldman Sachs Group boosted their price target on shares of Moderna from $137.00 to $195.00 and gave the stock a “neutral” rating in a report on Monday, November 9th. TD Cowen reaffirmed a “buy” rating on shares of Moderna in a report on Wednesday, October 21st. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Moderna in a report on Friday, September 25th. Singular Research upgraded shares of Moderna to a “hold” rating in a research report on Wednesday, September 23rd. Finally, Barclays lifted their target price on shares of Moderna from $48.00 to $125.00 and gave the company an “equal weight” rating in a research report on Monday, August 24th. Six equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $113.75.

Check Out Our Latest Stock Analysis on MRNA

Insider Activity at Moderna

In other Moderna news, President Stephen Hoge sold 40,294 shares of Moderna stock in a transaction on Monday, September 14th. The shares were sold at an average price of $144.13, for a total transaction of $5,807,574.22. Following the sale, the president owned 1,525,858 shares of the company’s stock, valued at $219,921,913.54. The trade was a 2.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the sale, the insider directly owned 74,129 shares in the company, valued at approximately $10,374,353.55. This trade represents a 4.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 197,251 shares of company stock valued at $33,875,904. 10.80% of the stock is owned by insiders.

Moderna News Summary

Investors following MRNA have been watching these news items:

  • Positive Sentiment: Moderna lifted its 2026 revenue-growth forecast to 15%–25%, from a previous outlook of up to 10%, citing commercial progress including stronger overseas COVID-19 sales. Article
  • Positive Sentiment: The company highlighted progress in its oncology pipeline, including its personalized cancer vaccine, positioning cancer treatments as a potential longer-term growth driver. Article
  • Negative Sentiment: Investors are concerned about roughly $4 billion in planned 2027 cash costs, much of it tied to pipeline investment, while visibility into future revenue growth remains limited. Coverage also noted that the 2026 revenue outlook may fall short of analyst expectations, tempering the more optimistic growth forecast. Article

Moderna Price Performance

Shares of Moderna stock opened at $223.37 on Monday. The stock has a market capitalization of $90.38 billion, a P/E ratio of -31.46 and a beta of 1.16. The business has a 50 day simple moving average of $201.67 and a two-hundred day simple moving average of $96.41. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $280.80. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.62 and a quick ratio of 3.47.

Moderna (NASDAQ:MRNA – Get Free Report) last issued its quarterly earnings results on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.10) by $1.48. The firm had revenue of $1.31 billion for the quarter, compared to analyst estimates of $890.25 million. Moderna had a negative return on equity of 25.79% and a negative net margin of 110.46%. The business’s revenue was up 29.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.51) earnings per share. As a group, analysts predict that Moderna, Inc. will post -5.14 EPS for the current fiscal year.

Moderna Profile

(Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

Further Reading

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Free Report).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.